Why the study?
Does cyclosporine reduce mortality in a murine viral myocarditis model?
Does cyclosporine reduce mortality in a murine viral myocarditis model?
Cyclosporine use in the early stages of viral myocarditis in mice enhanced anti-heart autoantibody production and was associated with a higher mortality rate.
Answers are grounded in this paper and cite their sources.
May increase early mortality in viral myocarditis models; challenges assumptions and leaves open human translation.
The effect of cyclosporine on the immunopathogenesis of viral myocarditis was studied using a murine viral myocarditis model. Mice in the treated group had a higher mortality rate compared with those of the infected control group before day 15 (47/67 vs. 14/31, p less than 0.05). On day 7, treated mice showed higher titers of anti-heart autoantibody than the control group (12 +/- 7 vs 4 +/- 2, p less than 0.05), but no significant difference was seen on day 14 (28 +/- 15 vs. 39 +/- 34). Histologic lesions, lymphocyte subsets in the peripheral blood and heart in situ, the neutralizing antibody, and virus concentrations in the heart showed no significant differences between these groups. This study suggests that with the use of cyclosporine the production of anti-heart autoantibody was enhanced in the early stages of viral myocarditis in mice, and was associated with higher mortality rate.
No takes yet. Share an insight, caveat, or question.
Matoba et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: